Publications by authors named "Heather Lankes"

Claim this Profile
M
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer.
Robert L Hollis, Austin Miller, Heather A Lankes, Kwong-Kwok Wong, William Rodgers

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.
Victoria L Bae-Jump, Michael W Sill, Paola A Gehrig, Jason D Merker, David L Corcoran, Heather A Lankes

Gynecol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of Timing for Risk-Reducing Salpingectomy and Oophorectomy.
Kathryn P Pennington, Stephanie L Pugh, Warner Huh, Joan L Walker, Elizabeth Jewell, Heather A Lankes

Obstet Gynecol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial.
Jyoti Mayadev, Dmitriy Zamarin, Wei Deng, Heather A Lankes, Giulio Pesci

Nat Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
Roisin E O'Cearbhaill, Austin Miller, Robert A Soslow, Heather A Lankes, Deborah DeLair

Gynecol Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.
Kathryn Osann, Lari Wenzel, Chelsea McKinney, Lynne Wagner, David Cella, Heather A Lankes

Gynecol Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
Kristina W Thiel, Eric J Devor, Virginia L Filiaci, David Mutch, Katherine Moxley, Heather A Lankes

J Clin Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study.
Yovanni Casablanca, Guisong Wang, Heather A Lankes, Chunqiao Tian, Nicholas W Bateman

Cancers (Basel)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.
Lari Wenzel, Kathryn Osann, Chelsea McKinney, David Cella, Giulia Fulci, Heather A Lankes

J Natl Cancer Inst· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.
Linda R Duska, Virginia L Filiaci, Joan L Walker, Laura L Holman, Emily K Hill, Heather A Lankes

Clin Cancer Res· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
Kimberly K Leslie, Virginia L Filiaci, Adrianne R Mallen, Kristina W Thiel, Eric J Devor, Heather Lankes

Gynecol Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer.
Melissa A Merritt, Howard D Strickler, Alan D Hutson, Mark H Einstein, Thomas E Rohan, Heather A Lankes

Cancer Epidemiol Biomarkers Prev· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biospecimen Collection During the COVID-19 Pandemic.
Heather A Lankes, Hala Makhlouf

Am J Clin Pathol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).
Diane M Da Silva, Danielle M Enserro, Jyoti S Mayadev, Joseph G Skeate, Koji Matsuo, Heather A Lankes

Clin Cancer Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).
Krishnansu S Tewari, Michael W Sill, Bradley J Monk, Richard T Penson, David H Moore, Heather A Lankes

Mol Cancer Ther· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532].
Alessandro D Santin, Virginia Filiaci, Stefania Bellone, Roisin O'Cearbhaill, Elena S Ratner, Heather A Lankes

Gynecol Oncol Rep· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: .
Jyoti Mayadev, Dmitriy Zamarin, Wei Deng, Heather Lankes, Roisin O’Cearbhaill

Int J Gynecol Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
Dmitriy Zamarin, Robert A Burger, Michael W Sill, Daniel J Powell, Heather A Lankes

J Clin Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.
Jyoti Mayadev, Dmitriy Zamarin, Wei Deng, Heather Lankes, Roisin O'Cearbhaill

Int J Gynecol Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
Alessandro D Santin, Wei Deng, Michael Frumovitz, Natalia Buza, Stefania Bellone, Heather A Lankes

Gynecol Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B Sibley, Heather A Lankes

Clin Cancer Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Lauren Krill, Wei Deng, Ramez Eskander, David Mutch, Susan Zweizig, Heather Lankes

Gynecol Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).
Alessandro D Santin, Virginia Filiaci, Stefania Bellone, Elena S Ratner, Cara A Mathews, Heather A Lankes

Gynecol Oncol Rep· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer.
Jyoti S Mayadev, Danielle Enserro, Yvonne G Lin, Diane M Da Silva, Heather A Lankes

JAMA Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study.
Roisin E O'Cearbhaill, Wei Deng, Lee-May Chen, Joseph A Lucci, Kian Behbakht, Heather A Lankes

Gynecol Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis